PURPOSE: The management of patients with mantle cell lymphoma (MCL) not eligible for stem cell transplantation in relapse after receiving standard approaches remains challenging, and the search for active and tolerable regimens is still warranted. PATIENTS AND METHODS: We have retrospectively analyzed activity of rituximab (375 mg/m(2) i.v. day 1), Ara-C (1,000 mg i.v. total twice daily on day 2) and oxaliplatin (130 mg/m(2) i.v. day 3) (R-ADOx) in 12 patients (median age 69 years) with relapsed MCL. RESULTS: Patients had been heavily pretreated (median 3 prior therapies, range 1-9) and had stage III/IV disease. Nine out of 12 patients responded (75 %, 4 CR, 5 PR). Median progression-free survival was 9.3 months, and overall survival has not been reached. Adverse events greater than grade II included anemia (17 %) and thrombocytopenia (33 %). CONCLUSION: R-ADOx is active and well tolerated in heavily pretreated MCL patients.
PURPOSE: The management of patients with mantle cell lymphoma (MCL) not eligible for stem cell transplantation in relapse after receiving standard approaches remains challenging, and the search for active and tolerable regimens is still warranted. PATIENTS AND METHODS: We have retrospectively analyzed activity of rituximab (375 mg/m(2) i.v. day 1), Ara-C (1,000 mg i.v. total twice daily on day 2) and oxaliplatin (130 mg/m(2) i.v. day 3) (R-ADOx) in 12 patients (median age 69 years) with relapsed MCL. RESULTS:Patients had been heavily pretreated (median 3 prior therapies, range 1-9) and had stage III/IV disease. Nine out of 12 patients responded (75 %, 4 CR, 5 PR). Median progression-free survival was 9.3 months, and overall survival has not been reached. Adverse events greater than grade II included anemia (17 %) and thrombocytopenia (33 %). CONCLUSION:R-ADOx is active and well tolerated in heavily pretreated MCLpatients.
Authors: Jia Ruan; Peter Martin; Morton Coleman; Richard R Furman; Ken Cheung; Adam Faye; Rebecca Elstrom; Mark Lachs; Katherine A Hajjar; John P Leonard Journal: Cancer Date: 2010-06-01 Impact factor: 6.860
Authors: Heather E Eve; Sean Carey; Sarah J Richardson; Carla C Heise; Vidya Mamidipudi; Tao Shi; John A Radford; Rebecca L Auer; Sheila H Bullard; Simon A J Rule Journal: Br J Haematol Date: 2012-08-09 Impact factor: 6.998
Authors: Wolfgang Lamm; Hannes Kaufmann; Markus Raderer; Martha Hoffmann; Andreas Chott; Christoph Zielinski; Johannes Drach Journal: Haematologica Date: 2011-04-12 Impact factor: 9.941
Authors: Georg Lenz; Martin Dreyling; Eva Hoster; Bernhard Wörmann; Ulrich Dührsen; Bernd Metzner; Hartmut Eimermacher; Andreas Neubauer; Hannes Wandt; Hjalmar Steinhauer; Sonja Martin; Else Heidemann; Ali Aldaoud; Reza Parwaresch; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann Journal: J Clin Oncol Date: 2005-01-24 Impact factor: 44.544
Authors: H C Kluin-Nelemans; E Hoster; O Hermine; J Walewski; M Trneny; C H Geisler; S Stilgenbauer; C Thieblemont; U Vehling-Kaiser; J K Doorduijn; B Coiffier; R Forstpointner; H Tilly; L Kanz; P Feugier; M Szymczyk; M Hallek; S Kremers; G Lepeu; L Sanhes; J M Zijlstra; R Bouabdallah; P J Lugtenburg; M Macro; M Pfreundschuh; V Procházka; F Di Raimondo; V Ribrag; M Uppenkamp; M André; W Klapper; W Hiddemann; M Unterhalt; M H Dreyling Journal: N Engl J Med Date: 2012-08-09 Impact factor: 91.245
Authors: F Hitz; G Martinelli; E Zucca; R von Moos; W Mingrone; M Simcock; J Peterson; S B Cogliatti; F Bertoni; D R Zimmermann; M Ghielmini Journal: Hematol Oncol Date: 2009-09 Impact factor: 5.271
Authors: Carlo Visco; Silvia Finotto; Renato Zambello; Rossella Paolini; Andrea Menin; Roberta Zanotti; Francesco Zaja; Gianpietro Semenzato; Giovanni Pizzolo; Emanuele S G D'Amore; Francesco Rodeghiero Journal: J Clin Oncol Date: 2013-02-11 Impact factor: 44.544
Authors: Georg Hess; Raoul Herbrecht; Jorge Romaguera; Gregor Verhoef; Michael Crump; Christian Gisselbrecht; Anna Laurell; Fritz Offner; Andrew Strahs; Anna Berkenblit; Orysia Hanushevsky; Jill Clancy; Becker Hewes; Laurence Moore; Bertrand Coiffier Journal: J Clin Oncol Date: 2009-07-06 Impact factor: 44.544
Authors: Stephen M Ansell; David J Inwards; Kendrith M Rowland; Patrick J Flynn; Roscoe F Morton; Dennis F Moore; Scott H Kaufmann; Irene Ghobrial; Paul J Kurtin; Matthew Maurer; Christine Allmer; Thomas E Witzig Journal: Cancer Date: 2008-08-01 Impact factor: 6.860